Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
Key Highlights
- ➤Vaxart appoints retired Vice Admiral Raquel C. Bono to its Board of Directors
- ➤Bono will chair Vaxart’s Stockholder Engagement Committee
- ➤Bono joins Vaxart board under a July 2026 stockholder cooperation agreement
- ➤Bono previously led the Defense Health Agency’s $50 billion healthcare system
- ➤Bono remains a Humana (HUM) board member
Expert Statements
W. Mark Watson, Lead Independent Director of Vaxart
“We are pleased to welcome Dr. Bono to the Vaxart Board”
W. Mark Watson, Lead Independent Director of Vaxart
“Her expertise at the intersection of medicine, public health and policy brings a unique perspective that will be important as we continue to advance our differentiated oral vaccine platform.”
W. Mark Watson, Lead Independent Director of Vaxart
“Vaxart is making progress toward a series of value-inflection milestones with the potential to redefine vaccine delivery and immune responses.”
W. Mark Watson, Lead Independent Director of Vaxart
“We look forward to working with Rocky to realize the full potential of the Vaxart platform for the benefit of all stockholders.”
Raquel C. Bono, Managing Partner of NAVA Edge LLC and Vaxart board member
“Vaxart has an opportunity to transform the future of vaccines, and I am excited to join the Board at such a pivotal time for the Company”
Raquel C. Bono, Managing Partner of NAVA Edge LLC and Vaxart board member
“As I’ve gotten to know my fellow directors, I have been impressed by the Board’s commitment to Vaxart and the thoughtful work underway to position the Company for success.”
Raquel C. Bono, Managing Partner of NAVA Edge LLC and Vaxart board member
“I look forward to building on that work, engaging with Vaxart’s stockholders to hear their perspectives, and helping Vaxart achieve its long-term goals.”
Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB: VXRT) (the “Company” or “Vaxart”), a clinical-stage biotechnology company developing a portfolio of oral recombinant vaccines based on its proprietary delivery platform, today announced the appointment of Raquel “Rocky” C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), to its Board of Directors.
Get started
Create a free account to read the full story.